This Issue at a Glance

Valsecchi et  al (p. 210) evaluated the use of sunitinib as adjuvant therapy in a group of uveal melanoma patients with a high risk of developing distant metastases. They conducted a retrospective cohort study on uveal melanoma patients diagnosed from January 2007 to January 2013 and selected from the database of the Ocular Oncology Service at Wills Eye Hospital. The researchers compared the overall survival of 54 patients who received adjuvant sunitinib for 6 months to 74 patients in the control group with the same risk factors.
Source: Ophthalmology - Category: Opthalmology Authors: Tags: This issue at a glance Source Type: research